drugset / Trial / NCT04015739
Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse
NaSingle-groupOpen-labelTreatment
Summary
Assessing the safety and efficacy of the bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patient with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at least one previous line of platinum-taxane chemotherapy, and present with platinum resistant disease (PRR) or platinum-sensitive relapse (PSR), whatever the line of chemotherapy given at relapse.
Timeline
- Start
- 2019-03-01
- Primary completion
- 2020-06-30
- Completion
- 2024-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 1.12 g | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | Oral |